Lupus nephritis is one of the most common and serious complications of systemic lupus erythematosus (SLE) in childhood affecting more than 80 % of patients. Treatment of this complication has undergone significant evolution in recent years. A series of randomized controlled trials has clarified the role of a variety of immunomodulating regimens including some novel biologic medications. This review touches on the major trials that have influenced practice and shaped current thinking about the treatment of proliferative lupus glomerulonephritis.
- Mycophenolate mofetil
- Pediatric lupus
- Systemic lupus erythematosus
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health